GlassScriptPhysician profile
Nancy Danielle Collins
NPI 1033586615
$1,100.70
in general payments reported to CMS, 2019-2025
20 companies · $65.80 in 2025
The $65.80 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $409 · 2022: $271 · 2023: $233 · 2024: $122 · 2025: $65.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $239.32 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $146.41 | 2021-2022 | |
| Celgene Corporation | $138.71 | 2021-2023 | Reblozyl |
| Merck Sharp & Dohme LLC | $110.24 | 2021-2022 | |
| Daiichi Sankyo INC. | $98.17 | 2021-2025 | Injectafer, Datroway |
| Amgen INC. | $60.27 | 2021-2023 | Lumakras, Kyprolis, Blincyto |
| Pfizer INC. | $59.29 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.05 | 2023 | Gilotrif |
| Array Biopharma INC | $24.36 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.33 | 2023 | Fruzaqla |
| Eisai INC. | $22.25 | 2024 | |
| Fennec Pharmaceuticals, INC. | $22.09 | 2025 | Fyarro |
| Pharmacosmos Therapeutics INC. | $19.47 | 2023 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $18.22 | 2021 | |
| Amag Pharmaceuticals, INC. | $17.59 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17.38 | 2024 | |
| Glaxosmithkline, LLC. | $16.72 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.32 | 2023 | Nubeqa |
| Genzyme Corporation | $13.64 | 2021 | |
| Boston Scientific Corporation | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.